Excelsior Correspondent
JAMMU, Apr 17: To strengthen drug quality standards and regulatory coordination, the first-ever scientific conclave and interactive session on the Indian Pharmacopoeia (IP) 2026 in Jammu and Kashmir was held at CSIR–Indian Institute of Integrative Medicine (IIIM), Jammu.
Organized by the Indian Pharmacopoeia Commission (IPC) under the Ministry of Health and Family Welfare in collaboration with CSIR-IIIM Jammu and the J&K Pharmaceutical Manufacturers Association, the day-long event brought together stakeholders from regulatory bodies, the pharmaceutical industry, academia and research institutions to deliberate on the implementation of the latest pharmacopoeial standards.
Director, CSIR-IIIM Jammu, Dr Zabeer Ahmed termed the conclave a “rare and valuable platform” connecting scientists, regulators and industry. He emphasized that while research institutions drive drug discovery, their translation into usable medicines depends on robust regulatory frameworks and industry participation. Highlighting the Himalayan region’s biodiversity, he stressed the need for strong regulatory support and GMP-compliant infrastructure for phyto-pharmaceutical development.
In his keynote address, Secretary-Cum-Scientific Director, IPC, Dr V Kalaiselvan described the conclave as a milestone for the region. He noted that IP 2026 includes over 3,000 monographs, reflecting India’s growing scientific autonomy. He added that the pharmacopoeia promotes ease of doing business, exports and reduced duplicate testing. He also highlighted IPC’s push for “green pharmacopoeia” and pharmacovigilance initiatives in J&K.
Senior Executive, J&K Drug Manufacturing Association, B L Koul termed IP 2026 a progressive framework aligned with global standards, urging manufacturers to prioritize quality and patient safety.
Assistant Drug Controller, CDSCO, Bharati Bachloo outlined strengthened enforcement mechanisms and highlighted the inclusion of blood component standards. J&K State Drug Controller, Rajesh Angurana called IP 2026 a blueprint for maintaining India’s status as the “pharmacy of the world.”
Technical sessions featured insights from Dr Vivek Mahajan, Dr Pawan Saini, Bharati Bachloo, Dr Robin Kumar and Dr Anil Kumar Teotia on impurities, monograph development and quality standards. Sukhwinder Singh and Dr Sangeeta Pahuja discussed blood component monographs.
The conclave concluded with an interactive session moderated by Bachloo while proceedings were conducted by Dr Gurleen Kaur.
Follow our WhatsApp channel
